Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

BACKGROUND: Neoadjuvant chemotherapy (NAC) is a standard treatment for stage II/III breast cancer patients, and response to NAC is a useful prognostic marker. Since its introduction, 6–8 cycles of NAC has become the standard regimen to improve the outcome of these patients. The purpose of this study...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Cancer
Asıl Yazarlar: Yang, Yaewon, Im, Seock-Ah, Keam, Bhumsuk, Lee, Kyung‑Hun, Kim, Tae‑Yong, Suh, Koung Jin, Ryu, Han Suk, Moon, Hyeong-Gon, Han, Sae‑Won, Oh, Do‑Youn, Han, Wonshik, Kim, Tae‑You, Park, In Ae, Noh, Dong-Young
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2016
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4955253/
https://ncbi.nlm.nih.gov/pubmed/27444430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2500-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller